Janssen Research & Development, Llc

This study tests whether adding the experimental drug bleximenib to two standard medicines (venetoclax and azacitidine) helps people with a specific genetic subtype of acute myeloid leukemia (AML) achieve remission and live longer. About 600 adults aged 18 and older who are newly…

This study tests a new drug called bleximenib for people with acute leukemia that has come back or not responded to other treatments. The drug targets specific genetic changes in the cancer cells. The goal is to find the best dose and see if it can safely help patients achieve re…

This study looks at the long-term safety of a drug called guselkumab in children with moderate to severe Crohn's disease, ulcerative colitis, or juvenile psoriatic arthritis. About 196 kids who already completed a previous guselkumab study and benefited from it will continue trea…

This study tests whether adding pasritamig (a drug that helps the immune system attack cancer cells) to standard chemotherapy (docetaxel) can delay cancer growth in men with metastatic castration-resistant prostate cancer. About 800 participants will be randomly assigned to recei…

This study follows people who already received an eye injection of JNJ-81201887 or a sham in earlier studies for geographic atrophy, a form of advanced age-related macular degeneration. The goal is to check long-term safety by monitoring side effects and eye health over time. Abo…

This study tests two different drug combinations for people with a common genetic form of advanced lung cancer (EGFR-mutated non-small cell lung cancer). One group gets a new drug (amivantamab) plus a targeted pill (lazertinib) as their first treatment. Another group gets amivant…

This study is testing a drug called bedaquiline (TMC207) in children and teens (0 to 18 years old) who have multidrug-resistant tuberculosis (MDR-TB). The goal is to see how safe the drug is, how the body processes it, and how well it works when given with other TB medicines. Abo…

This study tests a medicine called nipocalimab in pregnant people who have a high risk of a condition called hemolytic disease of the fetus and newborn (HDFN). HDFN can cause severe anemia in the baby, requiring risky blood transfusions while still in the womb. The goal is to see…

This study tests a drug called amivantamab, either alone or with standard chemotherapy, in people with advanced or metastatic colorectal cancer. The goal is to see if the drug can shrink tumors and to find the safest dose when combined with chemo. About 225 adults whose cancer ha…

This study tests a new drug called JNJ-88545223 in 240 adults with active psoriatic arthritis, a condition causing painful, swollen joints and skin patches. Participants will receive either the drug or a placebo to see if it reduces symptoms like joint pain and skin rashes. The g…

This early-phase study tests a combination of two experimental drugs for men with advanced prostate cancer that has spread and no longer responds to standard hormone therapy. The first drug helps the immune system attack cancer cells, while the second aims to boost that attack. A…

This early-stage study tests a new drug, JNJ-89853413, in people whose acute myeloid leukemia (AML) or myelodysplastic neoplasms (MDS) have returned or stopped responding to treatment. The main goals are to check safety and find the best dose. About 115 adults will take part in t…

This study looks at how well TAR-200 works for people with early-stage bladder cancer (NMIBC) in real-world settings. Researchers will measure how long it takes for the cancer to come back or get worse after starting TAR-200. About 150 participants who have already started TAR-20…

This early-stage study tests a combination of two experimental drugs for men with advanced prostate cancer that has spread and no longer responds to hormone therapy. One drug helps the immune system find and attack cancer cells, while the other delivers a toxic payload directly t…

This study tests a new drug called talquetamab for people with multiple myeloma, a type of blood cancer, that has returned or stopped responding to other treatments. The drug is designed to help the immune system attack cancer cells. About 510 adults will take part to see if the …

This study tests whether the drug icotrokinra can reduce symptoms and intestinal inflammation in people with moderate-to-severe Crohn's disease. About 1,092 participants will receive either the drug or a placebo to compare results. The goal is to see if icotrokinra helps achieve …

This study tests whether nipocalimab works better than efgartigimod for people with generalized myasthenia gravis, a condition where the immune system attacks nerve-muscle connections, causing weakness. About 115 adults will receive either drug, and some may switch from efgartigi…

This study tests whether adding the drug amivantamab to standard chemotherapy (FOLFIRI) helps people with advanced colorectal cancer live longer without their disease getting worse. It includes 700 adults whose cancer has returned or spread and who have a specific genetic profile…

This study tests a new drug called icotrokinra (JNJ-77242113) for people with active psoriatic arthritis, a condition causing joint pain and skin patches. About 750 adults who have tried other treatments will receive either the drug or a placebo. The goal is to see if the drug re…

This study compares two treatments for people with advanced left-sided colorectal cancer that cannot be removed by surgery. One group gets a new drug called amivantamab plus chemotherapy, while the other gets the standard drug cetuximab plus chemotherapy. The goal is to see which…

This early-stage study is testing an experimental drug called JNJ-89862175 for people with advanced solid tumors that have spread or cannot be removed. The drug is designed to target and kill cancer cells. The main goals are to find a safe dose and to check for side effects. Abou…

This study tests a new drug, nipocalimab, in about 199 adults with generalized myasthenia gravis, a condition that causes muscle weakness. The goal is to see if nipocalimab improves daily activities and muscle strength better than a placebo. The drug is given either through a vei…

This early-phase study tests an experimental drug called JNJ-79635322, a trispecific antibody designed to attack cancer cells in multiple ways. It is for people with multiple myeloma or AL amyloidosis that has returned or not responded to prior treatments. The main goals are to f…

This study tests a new treatment called TAR-210 (a drug placed directly into the bladder) against standard chemotherapy for people with a high-risk type of bladder cancer that has certain genetic changes (FGFR alterations). Participants must have already received BCG therapy. The…

This early-phase study tests an experimental drug called JNJ-89402638 in people with advanced colorectal or stomach cancer that has spread and not responded to prior treatments. The main goals are to find a safe dose and check for side effects, both when the drug is given alone a…

This study tests a new drug called pasritamig, which helps the body's immune cells attack prostate cancer cells. It is for people with advanced prostate cancer that has spread and no longer responds to hormone therapy. About 663 participants will receive either pasritamig plus be…

This early-stage study is testing a new drug called JNJ-95437446 in about 380 adults with advanced solid tumors, including colorectal, lung, and head and neck cancers that have spread or cannot be removed. The main goals are to find safe doses and check for side effects. Research…

This study offers ongoing access to the drug ibrutinib for up to 700 people with certain blood cancers (like chronic lymphocytic leukemia or mantle cell lymphoma) who are already taking it and benefiting. The goal is to track long-term safety and see how well the drug controls th…

This study offers ongoing access to daratumumab for up to 500 multiple myeloma patients who are already benefiting from it in other studies. Participants will continue their treatment while researchers monitor long-term safety, including serious side effects and infections. The g…

This study is testing an experimental drug called nipocalimab in children aged 2 to 18 with generalized myasthenia gravis, a condition that causes muscle weakness. The goal is to see if the drug can safely lower harmful antibodies and improve daily activities. About 12 children w…

This early-phase study tests an experimental drug called JNJ-95566692, alone or with another drug, in people with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior treatments. The main goals are to find a safe dose and check for side effects. A…

This early-phase study tests an experimental drug, JNJ-88549968, designed to help the immune system attack cancer cells with a specific CALR mutation. About 220 adults with essential thrombocythemia or myelofibrosis will receive the drug to find the safest dose and schedule. The …

This study tests a drug called amivantamab, alone or with other cancer treatments, in people with head and neck cancer that has spread or come back. About 287 adults will take part to see if the drug shrinks tumors and to find the safest dose. The goal is to control the disease, …

This early-stage trial tests a new drug (JNJ-78278343) combined with other treatments for men with metastatic prostate cancer that no longer responds to hormone therapy. The study involves 300 participants and aims to find the safest dose and check for side effects. It is not a c…

This early-phase study tests a new drug called JNJ-87890387 in people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safety and find the best dose. About 200 adults with certain cancers (like kidney, ovarian, uterine, colorectal, or …

This early-stage study is testing two experimental drugs (JNJ-87189401 and JNJ-78278343) together in people with advanced prostate cancer. The main goals are to find the best dose and check for side effects. About 250 participants will take part in this research.

This study tests a drug called nipocalimab in adults with chronic inflammatory demyelinating polyneuropathy (CIDP), a condition where the immune system attacks nerves, causing weakness and numbness. The goal is to see if nipocalimab can delay relapses compared to a placebo. About…

This study tests a new medicine called nipocalimab against a standard treatment (IVIG) in 50 pregnant women who have had a previous pregnancy affected by FNAIT, a condition where the mother's immune system attacks the baby's platelets. The goal is to see if nipocalimab can better…

This early-phase study tests a new drug, JNJ-90189892, in people with acute myeloid leukemia or myelodysplastic neoplasms that returned or didn't respond to treatment. The main goal is to find a safe dose and check for side effects. About 155 adults will take part, and later part…

This study tests a new drug, JNJ-79635322, against another targeted therapy for people with multiple myeloma that has come back or stopped responding after at least three prior treatments. About 400 adults will be randomly assigned to one of the two treatments to see which works …

This study tests a daily pill called milvexian to see if it can prevent another stroke in people who have recently had a stroke or a high-risk mini-stroke. About 15,000 participants will be randomly assigned to receive either milvexian or a placebo. The goal is to find a safer wa…

This study tests a drug called seltorexant, taken with an antidepressant, to see if it improves depression and insomnia symptoms. About 752 adults with major depression and poor sleep who haven't responded well enough to current antidepressants will participate. The study is doub…

This study tests whether special skin care can reduce rashes and other skin problems caused by a lung cancer drug combination (amivantamab + lazertinib). About 300 people with advanced EGFR-mutated non-small cell lung cancer will be randomly assigned to standard skin care or enha…

This study tests whether a nasal spray containing esketamine, given alongside standard care, can quickly reduce symptoms of major depression and suicidal thoughts in teenagers. About 258 adolescents with acute suicidal feelings will receive either the active spray or a placebo th…

This study tests an experimental drug called JNJ-89495120 to see if it can quickly reduce depression symptoms in adults with major depressive disorder. About 124 participants will receive either the drug or a placebo, and researchers will measure mood changes using a standard dep…

This study looks at how the body absorbs, breaks down, and gets rid of a drug called bleximenib in 10 adults with acute leukemia (a fast-growing blood cancer). Participants receive a single dose of the drug with a radioactive tag so researchers can follow it. The goal is to under…

This study follows 175 pregnant people who have a blood type mismatch with their baby, putting the baby at risk for hemolytic disease of the fetus and newborn (HDFN). Researchers will track how often babies develop severe anemia, need blood transfusions before birth, or face othe…

This study follows about 380 people with a common type of advanced lung cancer that has a specific gene change (EGFR mutation). Participants are already getting a drug called amivantamab as part of their normal care. The goal is to see how long they stay on treatment and how well…

This study looks at sleep patterns in 80 people with major depressive disorder, comparing those with moderate-to-severe insomnia to those with little or no insomnia. Participants wear a headband at home that records brain activity during sleep and also fill out sleep diaries and …

This study follows about 295 people with multiple myeloma who have already received the cell therapy cilta-cel. The goal is to watch for any delayed side effects, such as new cancers, nerve problems, or serious infections. Participants will have regular check-ups over several yea…